Across TCGA pan-cancer cohorts, UBE2S Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2S data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher UBE2S Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2S expression acts as an unfavorable survival marker.
THYM and BLCA are the cancer types where UBE2S Mutation most reproducibly stratifies survival.